Skip to main content
Clinical Trials/NCT06041334
NCT06041334
Recruiting
Not Applicable

Evaluation of muLtimodal and Non-invasive SPINa Bifida Neurovessels During Prospective Follow-up

Rennes University Hospital1 site in 1 country50 target enrollmentJanuary 18, 2024

Overview

Phase
Not Applicable
Intervention
Collection of a urine sample
Conditions
Spina Bifida
Sponsor
Rennes University Hospital
Enrollment
50
Locations
1
Primary Endpoint
Verify if levels of urinary biomarkers Metalloproteinase Inhibitor 2 and matrix metalloproteinase-2 are associated with Galloway score
Status
Recruiting
Last Updated
4 months ago

Overview

Brief Summary

The aim of the study is to investigate known urinary biomarkers in order to determine whether they can be predictive of a risk of damage to the upper urinary tract and therefore the kidneys in patients with spina bifida. The risk of damage to the upper urinary tract can be calculated using the Galloway score, based on the results of the urodynamic study and retrograde urethrocystography, which all patients with spina bifida have regularly.

The urinary biomarkers studied TIMP-2 (Tissue inhibitor of metalloproteinases 2) and MMP-2 (matrix metalloproteinase-2) are potentially associated with renal degradation, but this has not yet been demonstrated.

Volunteers to take part in the study will have their biomarkers measured at the time of their urodynamic assessment.

Registry
clinicaltrials.gov
Start Date
January 18, 2024
End Date
July 18, 2028
Last Updated
4 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Rennes University Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Spina patients consulted as part of the multidisciplinary consultation of the spina bifida rare disease reference centre;
  • Written consent to participate in the research.
  • Compulsory membership of a social security scheme

Exclusion Criteria

  • Patients with a non-continuous trans ileal urinary diversion ;
  • Patients with enterocystoplasty;
  • Untreated bacteriuria at the time of urodynamic assessment and urine sample collection;
  • History of urinary tract tumour;
  • History of histologically proven interstitial cystitis;
  • Persons under legal protection (safeguard of justice, curatorship, guardianship);
  • Persons deprived of their liberty.
  • Women claiming to be pregnant

Arms & Interventions

Study volunteers

Intervention: Collection of a urine sample

Study volunteers

Intervention: Magnetic Resonance Imaging of the bladder

Outcomes

Primary Outcomes

Verify if levels of urinary biomarkers Metalloproteinase Inhibitor 2 and matrix metalloproteinase-2 are associated with Galloway score

Time Frame: 1 day

Logistic regression based on composite analysis of Galloway score (≤ 5 (low risk) or \>5 (high risk)) and the rate of urinary biomarkers.

Secondary Outcomes

  • Galloway score(1 year)
  • Success or failure of treatment(1 year)
  • Relationship between the success of the treatment implemented at inclusion and the level of urinary biomarkers(1 year)
  • Bladder hypocompliance based on metabolomic profile at inclusion(0 day)
  • Bladder hypocompliance based on MRI radiomic markers at inclusion(0 day)
  • Bladder hypocompliance based on MRI radiomic markers at 1 year(1 year)
  • Presence of biomarkers on bladder histological specimens(From enrollment to 1 year)

Study Sites (1)

Loading locations...

Similar Trials